Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia

Silvia G. Priori, Carlo Napolitano, Mirella Memmi, Barbara Colombi, Fabrizio Drago, Maurizio Gasparini, Luciano DeSimone, Fernando Coltorti, Raffaella Bloise, Roberto Keegan, Fernando E S Cruz Filho, Gabriele Vignati, Abraham Benatar, Angelica DeLogu

Research output: Contribution to journalArticlepeer-review


Background - Mutations in the cardiac ryanodine receptor gene (RyR2) underlie catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited arrhythmogenic disease occurring in the structurally intact heart. The proportion of patients with CPVT carrying RyR2 mutations is unknown, and the clinical features of RyR2-CPVT as compared with nongenotyped CPVT are undefined. Methods and Results - Patients with documented polymorphic ventricular arrhythmias occurring during physical or emotional stress with a normal heart entered the study. The clinical phenotype of the 30 probands and of 118 family members was evaluated, and mutation screening on the RyR2 gene was performed. Arrhythmias documented in probands were: 14 of 30 bidirectional ventricular tachycardia, 12 of 30 polymorphic ventricular tachycardia, and 4 of 30 catecholaminergic idiopathic ventricular fibrillation; RyR2 mutations were identified in 14 of 30 probands (36% bidirectional ventricular tachycardia, 58% polymorphic ventricular tachycardia, 50% catecholaminergic idiopathic ventricular fibrillation) and in 9 family members (4 silent gene carriers). Genotype-phenotype analysis showed that patients with RyR2 CPVT have events at a younger age than do patients with nongenotyped CPVT and that male sex is a risk factor for syncope in RyR2-CPVT (relative risk=4.2). Conclusions - CPVT is a clinically and genetically heterogeneous disease manifesting beyond pediatric age with a spectrum of polymorphic arrhythmias. β-Blockers reduce arrhythmias, but in 30% of patients an implantable defibrillator may be required. Genetic analysis identifies two groups of patients: Patients with nongenotyped CPVT are predominantly women and become symptomatic later in life; patients with RyR2 CPVT become symptomatic earlier, and men are at higher risk of cardiac events. These data provide a rationale for prompt evaluation and treatment of young men with RyR2 mutations.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
Issue number1
Publication statusPublished - Jul 1 2002


  • Arrhythmia
  • Catecholamines
  • Death, sudden
  • Genetics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia'. Together they form a unique fingerprint.

Cite this